Sobi Posts Strong 2025 Growth and Expands Rare Disease Portfolio With Strategic Deals and Launches

An announcement from Swedish Orphan Biovitrum AB ( (SE:SOBI) ) is now available.

Sobi closed 2025 with strong operational momentum, reporting fourth-quarter revenue growth of 16% at constant exchange rates and an adjusted EBITA margin of 41%, driven mainly by a 25% haematology increase and robust demand for Altuvoct and Doptelet, while full-year revenue rose 15% at constant exchange rates and margin reached 40%. The company’s strategic portfolio now represents 65% of revenue and grew 37% at constant exchange rates, underpinned by continued launches of Altuvoct and Gamifant, the EU launch of Tryngolza for familial chylomicronaemia syndrome, regulatory submissions for Aspaveli and NASP, and the planned acquisition of Arthrosi Therapeutics to strengthen its gout franchise; Sobi guided for low double‑digit revenue growth and mid‑30s adjusted EBITA margin in 2026 and opted against paying a dividend for 2025 to support its growth agenda.

The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK420.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.

More about Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB (Sobi) is a biopharmaceutical company focused on treatments for rare diseases, with core franchises in haematology and immunology. Its portfolio includes haemophilia therapies such as Altuvoct, thrombocytopenia treatment Doptelet, and immune disorder drugs like Gamifant and Kineret, while it is also expanding into specialty care areas including familial chylomicronaemia syndrome, severe hypertriglyceridemia and gout through in-house development and targeted acquisitions.

Average Trading Volume: 403,461

Technical Sentiment Signal: Buy

Current Market Cap: SEK123.6B

See more insights into SOBI stock on TipRanks’ Stock Analysis page.